Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poniard Plans 2009 NDA For “New Generation” Platinum-Based Chemotherapy Picoplatin

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm hopes ongoing studies will support three-pronged safety and efficacy benefit showing the oncologic overcomes platinum resistance, is neuropathy sparing and combines well with other treatments.

You may also be interested in...



Poniard’s Picoplatin Shows Good Tox Profile In Early ASCO Abstracts

Data from Phase III lung cancer trial due in third quarter.

Poniard’s Picoplatin Shows Good Tox Profile In Early ASCO Abstracts

Data from Phase III lung cancer trial due in third quarter.

Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase

Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.

Related Content

Topics

UsernamePublicRestriction

Register

PS065427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel